- Home
- CHCO vs GLPG Comparison
CHCO vs GLPG Comparison
Compare CHCO & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCO
- GLPG
- Stock Information
- Founded
- CHCO 1957
- GLPG 1999
- Country
- CHCO United States
- GLPG Belgium
- Employees
- CHCO N/A
- GLPG N/A
- Industry
- CHCO Major Banks
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- CHCO Finance
- GLPG Health Care
- Exchange
- CHCO Nasdaq
- GLPG Nasdaq
- Market Cap
- CHCO 1.8B
- GLPG 2.1B
- IPO Year
- CHCO N/A
- GLPG 2005
- Fundamental
- Price
- CHCO $123.20
- GLPG $34.67
- Analyst Decision
- CHCO Hold
- GLPG Sell
- Analyst Count
- CHCO 3
- GLPG 3
- Target Price
- CHCO $132.33
- GLPG $26.00
- AVG Volume (30 Days)
- CHCO 85.0K
- GLPG 199.1K
- Earning Date
- CHCO 10-23-2025
- GLPG 10-29-2025
- Dividend Yield
- CHCO 2.58%
- GLPG N/A
- EPS Growth
- CHCO 6.95
- GLPG N/A
- EPS
- CHCO 8.30
- GLPG N/A
- Revenue
- CHCO $300,872,000.00
- GLPG $323,674,692.00
- Revenue This Year
- CHCO $9.69
- GLPG $1.77
- Revenue Next Year
- CHCO $1.71
- GLPG $0.44
- P/E Ratio
- CHCO $14.76
- GLPG N/A
- Revenue Growth
- CHCO 4.61
- GLPG 5.43
- 52 Week Low
- CHCO $102.22
- GLPG $22.36
- 52 Week High
- CHCO $137.28
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- CHCO 43.84
- GLPG 56.01
- Support Level
- CHCO $121.30
- GLPG $34.62
- Resistance Level
- CHCO $124.78
- GLPG $37.78
- Average True Range (ATR)
- CHCO 2.21
- GLPG 0.77
- MACD
- CHCO -0.33
- GLPG 0.11
- Stochastic Oscillator
- CHCO 15.00
- GLPG 47.87
About CHCO City Holding Company
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.